10-QPeriod: Q2 FY1995

AMGEN INC Quarterly Report for Q2 Ended Jun 30, 1995

Filed August 11, 1995For Securities:AMGN

Summary

Amgen Inc. (AMGN) filed its 10-Q for the period ending June 29, 1995. While the provided filing snippet does not contain detailed financial statements or management discussion, it indicates a period of operational activity. Investors should note that this filing is from 1995, and significant company developments have occurred since then. The focus for investors at this historical juncture would have been on the company's product pipeline, regulatory approvals, and the commercial success of its existing therapies, particularly EPO (Erythropoietin) and G-CSF (Granulocyte Colony-Stimulating Factor). Given the limited information in the provided text, a deeper dive into the actual financial performance, revenue streams, and strategic outlook would require accessing the full 10-Q document. However, as a biotechnology leader in the mid-1990s, Amgen's growth trajectory and its ability to navigate the complex pharmaceutical market were key areas of investor interest. Any information on clinical trial progress or new drug applications would have been particularly scrutinized.

Key Highlights

  • 1Amgen Inc. (AMGN) filed its quarterly report (10-Q) for the period ending June 29, 1995.
  • 2The filing date was August 10, 1995, indicating timely reporting.
  • 3The provided text is a directory listing from the SEC EDGAR database, not the full financial report content.
  • 4Key historical products for Amgen around this time included EPO (Epogen) and G-CSF (Neupogen).
  • 5Investors would have been interested in the commercial performance and market penetration of these flagship products.
  • 6The company's pipeline and ongoing research and development efforts in biotechnology were critical for future growth.
  • 7Regulatory approvals and the competitive landscape in the biopharmaceutical sector were significant factors for investor consideration.

Frequently Asked Questions

The provided filing excerpt is a directory listing and does not contain specific financial performance data such as revenue, net income, or earnings per share. To understand the financial performance, the complete 10-Q filing document would need to be reviewed for detailed financial statements and the Management's Discussion and Analysis.

In 1995, Amgen's primary revenue drivers were its biotechnology-based therapies, notably Epogen (epoetin alfa) for anemia associated with chronic kidney disease and cancer chemotherapy, and Neupogen (filgrastim) to increase white blood cell counts in patients undergoing chemotherapy. These products were foundational to the company's financial success during that period.

While not present in the excerpt, a 10-Q filing from this era would typically detail the company's financial results, material events, any significant litigation, and updates on clinical trials and regulatory status of its product pipeline. For Amgen in 1995, this could have included progress on new indications for existing drugs or early-stage development of new biotechnology compounds.

Amgen has evolved significantly since 1995, expanding its product portfolio into numerous therapeutic areas such as cardiovascular disease, oncology, inflammation, and bone health, with many new blockbuster drugs. The company has also grown substantially in terms of revenue, market capitalization, and global reach, and has continued to invest heavily in research and development to maintain its leadership in biotechnology.